{"prompt": "['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', '5', 'ELIGIBILITY CRITERIA', 'This eligibility checklist is used to determine patient eligibility and filed with the enrolling', \"investigator's signature in the patient research chart.\", 'Patient No.', \"Patient's Initials: (L,F,M)\", '5.1', 'Inclusion Criteria', 'Yes/No (Response of \"no\" = patient ineligible)', '5.1.1', 'Male subject aged > 18 years.', '5.1.2', 'Histologically diagnosed adenocarcinoma of the prostate.', '5.1.3', 'Radiographically confirmed metastatic disease prior to patient enrollment.', 'Metastatic disease can be confirmed based on conventional imaging (CT, MRI,', 'nuclear medicine bone scan) or molecular imaging (fluciclovine-PET/CT, PSMA-', 'PET/CT, Choline-PET/CT etc).', '5.1.4', 'ECOG Performance Status 2.', '5.1.5', 'Adequate organ function as defined as:', 'Hematologic:', 'Absolute neutrophil count (ANC) > 1.5 k/L.', 'Platelets > 100 k/L.', 'Hepatic:', 'Serum total bilirubin 1.5 times upper limit of normal (ULN) OR direct', 'bilirubin ULN for subjects with total bilirubin > 1.5 X ULN.', 'AST or ALT 2.5 X ULN OR 4 X ULN for subjects with liver', 'metastases.', 'Renal:', 'Creatinine < 1.5 X ULN OR', 'Creatinine clearance > 50 mL/min for subject with creatinine levels > 1.5', 'ULN by Cockcroft-Gault fomula or standard institutional practice:', '(140-age)xweight(kg)', 'Males:', 'serum creatinine', 'mg', 'x72', 'dL', 'Females:', '(140-age) xweight[kg]', 'X 0.85', 'serum creatinine', 'mg', 'x72', 'dL', 'Page 20 of 52']['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', '5.1.6', 'Highly effective method of contraception for both male and female partners of', 'subjects throughout the study and for at least 3 months after last study treatment', 'administration if the risk of conception exists.', '5.1.7', 'Recovery to baseline or VI Grade 1 CTCAE v5.0 from toxicities related to any', 'prior treatments, unless AE(s) are clinically nonsignificant and/or stable on', 'supportive therapy as defined by the treating physician.', '5.1.8', 'Able to provide informed consent and willing to sign an approved consent', 'form that conforms to federal and institutional guidelines.', '5.2', 'Exclusion Criteria', 'Yes/No (Response of \"yes\" = patient ineligible)', '5.2.1', 'No prior abiraterone or docetaxel therapy for metastatic hormone sensitive', 'prostate cancer. Prior therapy with ADT or first generation anti-androgen receptor', 'therapy (example: bicalutamide) is allowed.', '5.2.2', 'Completed any hormone therapy for localized prostate cancer and have', 'recovery of testosterone (i.e. testosterone level is >50ng/dL).', '5.2.3', 'Patients have a histologic diagnosis of small cell prostate cancer or pure', 'squamous cell prostate cancer.', '5.2.4', 'Known brain metastases or cranial epidural disease unless adequately treated', 'with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4', 'weeks before first dose of study treatment. Eligible subjects must be neurologically', 'asymptomatic and without corticosteroid treatment at the time of first dose of study', 'treatment.', '5.2.5', 'The subject has uncontrolled, significant intercurrent or recent illness', 'including, but not limited to, the following conditions:', 'Cardiovascular disorders:', 'Congestive heart failure New York Heart Association Class 3 or 4, unstable', 'angina pectoris, serious cardiac arrhythmias within 3 months of study', 'enrollment.', 'Uncontrolled hypertension defined as sustained blood pressure (BP) > 170', 'mm Hg systolic or > 100 mm Hg diastolic despite optimal antihypertensive', 'treatment.', 'Stroke (including transient ischemic attack [TIA]), myocardial infarction', '(MI), or other ischemic event, or arterial thromboembolic event within 3', 'months before first dose.', 'Other clinically significant disorders that would preclude safe study participation.', 'As defined by the treating physician', 'Page 21 of 52']\n\n###\n\n", "completion": "END"}